Pathogenesis and inflammaging in MDS [MDS Professional Report]
Feb 1, 2025 - 28:47
Radio and PodcastLive Radio & Podcasts![Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report] artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/7b8bc7d62bbbfefa1a0c2f97a3d163fe.jpg)
Health
Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report]
Chien Aza – Pembro - BJH The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and may lead to the introduction of an important class of medications into...
Related Episodes
Continue listening to more episodes from MDS Professional Report.
Treatment of lower-risk MDS [MDS Professional Report]
Dec 15, 2024 - 28:57
Treatment for Higher-risk MDS [MDS Professional Report]
Dec 1, 2024 - 28:49
Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]
May 27, 2024 - 21:49
New trials to address the anemia of lower-risk MDS [MDS Professional Report]
Mar 27, 2024 - 27:58
Transfusions and quality of life [MDS Professional Report]
May 1, 2023 - 21:49
Bone marrow failure disorders in childhood [MDS Professional Report]
Dec 5, 2022 - 22:31
The role of genetics in MDS management [MDS Professional Report]
Sep 28, 2022 - 22:02